Mindset Pharma is a clinical-stage biopharmaceutical company developing small-molecule drug candidates to treat central nervous system disorders, particularly schizophrenia, major depressive disorder, and Parkinson's disease. The company's lead program is roluperidone, a serotonin-dopamine activity modulator in clinical development for negative symptoms of schizophrenia. As a pre-commercial, development-stage company, Mindset has no approved products or product revenue and funds its operations through equity offerings, debt financing, and strategic partnerships; success depends on achieving regulatory approval, demonstrating clinical efficacy and safety, gaining market acceptance, and establishing commercial capabilities in competitive markets with substantial unmet medical needs.